Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
Drug Discovery Today|May 15, 2012
Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for painDavid Borsook, Jaymin Upadhyay, Michael Klimas, et al.Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Revolutionizing Alzheimer's disease and clinical trials through biomarkersNiklas Mattsson, Maria C Carrillo, Robert A Dean, et al.Proteomics. Clinical Applications|February 14, 2015
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSFDaniel S Spellman, Kristin R Wildsmith, Lee A Honigberg, et al.Journal of Alzheimer'S Disease : JAD|November 14, 2014
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohortJeffrey L Seeburger, Daniel J Holder, Marc Combrinck, et al.Journal of Proteome Research|January 25, 2007
Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical modelSandeep T Patil, Richard E Higgs, John E Brandt, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2015
Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)Enchi Liu, Johan Luthman, Jesse M Cedarbaum, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 17, 2020
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2021
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseOndrej Libiger, Leslie M Shaw, Mark H Watson, et al.Journal of Affective Disorders|July 19, 2023
Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS studySabrina M Darrow, Diego A Pizzagalli, Moria Smoski, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersKellen K Petersen, Marta Milà-Alomà, Duygu Tosun, et al.Pageof 7